Get started
Author

Giacomo Nuvola

Observed names: G. Nuvola, Nuvola G, Nuvola, Giacomo
ORCID: 0000-0002-9498-5466
Observed ORCID: 0000-0002-9498-5466
OpenAlex ID: A5078751201
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
2021 · Andrea De Giglio, Alessandro Di Federico, et al. · Current Oncology Reports · 83
PDF
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 · Filippo G. Dall’Olio, Nicole Conci, et al. · Lung Cancer · 38
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
2021 · Andrea Marchetti, Matteo Rosellini, et al. · International Journal of Molecular Sciences · 35
PDF
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
2021 · Veronica Mollica, Andrea Marchetti, et al. · International Journal of Molecular Sciences · 34
PDF
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 · Alessandro Rizzo, Veronica Mollica, et al. · Cancers · 31
PDF
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
2022 · Andrea Marchetti, Matteo Rosellini, et al. · Cancers · 21
PDF
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect
2019 · Giacomo Nuvola, Filippo Gustavo Dall'Olio, et al. · Journal of Thoracic Oncology · 19
Has breast cancer in the elderly remained the same over recent decades? A comparison of two groups of patients 70years or older treated for breast cancer twenty years apart
2014 · Isacco Montroni, Maddalena Rocchi, et al. · Journal of Geriatric Oncology · 18
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 · Veronica Mollica, Giacomo Nuvola, et al. · Current Oncology · 15
PDF
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022 · Elisa Tassinari, Veronica Mollica, et al. · Cancer Management and Research · 12
PDF
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 · Veronica Mollica, Francesco Massari, et al. · Current Oncology · 11
PDF
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients with Brain Metastases
2021 · Vincenzo Di Nunno, Giacomo Nuvola, et al. · Immunotherapy · 10
PD-(L)1 Inhibitors as Single-Agent or in Combination with Chemotherapy for Advanced, PD-L1-high Non-Small Cell Lung Cancer: A Meta-Analysis
2021 · Alessandro Di Federico, Andrea De Giglio, et al. · Future Oncology · 9
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 · Alessandro Di Federico, Giacomo Nuvola, et al. · Anti-Cancer Drugs · 9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023 · Matteo Rosellini, Elisa Tassinari, et al. · Expert Opinion on Drug Safety · 8
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer
2023 · Giacomo Nuvola, Matteo Santoni, et al. · Expert Review of Anticancer Therapy · 7
The Future of Immunotherapy in Advanced Renal Cell Carcinoma: Beyond PD-1/PD-L1 Inhibitors
2023 · Giacomo Nuvola, Veronica Mollica, et al. · Immunotherapy · 6
Clinical Consideration for Choosing Combination Therapies in Advanced Non-Small-Cell Lung Cancer: Age, Eastern Cooperative Organization Performance Status 2, Steroids and Antibiotics
2020 · Andrea De Giglio, Giacomo Nuvola, et al. · Future Oncology · 6
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.
2023 · Giacomo Nuvola, David Humberto Marmolejo Castañeda, et al. · Journal of Clinical Oncology · 4
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 · Matteo Rosellini, Andrea Marchetti, et al. · Expert Review of Precision Medicine and Drug Development · 4
Hypertransaminasemia in Metastatic Renal Cell Carcinoma Patients Receiving Immune-Based Combinations: A Meta-Analysis
2023 · Alessandro Rizzo, Giacomo Nuvola, et al. · Immunotherapy · 3
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
2022 · Paola Valeria Marchese, Veronica Mollica, et al. · Pathology - Research and Practice · 3
The Dilemma of Neoadjuvant and Adjuvant Therapy in Urothelial Carcinoma: will Immunotherapy Solve the Problem?
2022 · Giacomo Nuvola, Alessandro Rizzo, et al. · Immunotherapy · 3
The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib.
2021 · Andrea De Giglio, Alessandro Di Federico, et al. · Journal of Clinical Oncology · 3
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
2021 · Alessandro Di Federico, Giacomo Nuvola, et al. · Journal of Thoracic Oncology · 2
Works count: 36
Citation count: 397
H-index: 11
I10-index: 12
Year
Topic
Type